Reliance Industries Q1 Results: Shares in focus as revenue jump 6% YoY to Rs 2.73 lakh crore, net profit rises 76.5% YoY
The surge was driven by strong performances across its telecom, retail, and oil-to-chemicals divisions. Consolidated EBITDA also reached a record ₹58,024 crore, reflecting a 35.7% year-on-year jump. The EBITDA margin expanded to 21.2%, up from 16.6% a year ago, backed by improved profitability across key business segments. Gross revenue grew 6% year-on-year to ₹2.73 lakh crore for the quarter ended June 30, 2025.
Jio Platforms posted strong results, with revenue up 18.8% and a healthy jump in EBITDA, supported by a growing 5G user base now crossing 200 million. Reliance Retail continued to expand, benefiting from strong demand across categories like grocery, fashion, and digital commerce. The oil-to-chemicals segment saw a slight revenue dip due to lower crude prices, but improved margins led to higher EBITDA. The oil and gas business reported a slight decline in both revenue and earnings due to production and maintenance factors. JioStar Media made a solid debut, riding on record IPL viewership, delivering over ₹11,000 crore in revenue.
Capital expenditure for the quarter stood at ₹29,875 crore, and net debt remained steady at ₹1.17 lakh crore. The company also noted progress in home broadband, with over 20 million connections, and ongoing momentum in digital offerings like JioGames Cloud and JioPC. Retail expansion continued at a strong pace with 388 new stores added in the quarter.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash Reliance IndustriesStock Market
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Tilaknagar Industries to acquire Imperial Blue business division from Pernod Ricard for Rs 4,150 crore
Tilaknagar Industries (TI), a key player in India's alcoholic beverages space, is making headlines with a landmark acquisition. The company has signed a definitive agreement to buy the Imperial Blue whisky business division from Pernod Ricard India for approximately ₹4,150 crore (€412.6 million), through a slump sale deal. A part of the payment—€28 million (around ₹282 crore)—will be deferred and paid four years after the deal closes. This acquisition marks TI's biggest move yet, helping the company enter the whisky market in a big way. Imperial Blue, the third-largest whisky brand in India by volume, sold 22.4 million 9-litre cases in FY25 and generated revenue of ₹3,067 crore. The deal also includes two owned manufacturing units and access to several co-manufacturing partners across India. Best known for its popular Mansion House Brandy, Tilaknagar Industries now aims to scale its presence across both the brandy and whisky segments, with a combined annual volume of 34 million cases. The acquisition fast-tracks TI's goal of becoming a major whisky player and expanding its distribution footprint pan-India. TI will use a mix of debt and equity to fund the acquisition, which is subject to CCI approval and is expected to close in six months. Deutsche Bank and Avendus Capital advised the deal, with legal and diligence support from Crawford Bayley, W.S. Kane, and Deloitte. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
7 hours ago
- Business Upturn
BEML bags defence order worth Rs 293.82 crore for supply of HMV 6×6 vehicles
BEML Limited has announced that it has secured a fresh order worth approximately ₹293.82 crore from the Ministry of Defence for the supply of High Mobility Vehicles (HMV) 6X6. The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015. This new contract strengthens BEML's position as a key defence equipment supplier, highlighting its capability to deliver advanced, indigenous mobility solutions for the armed forces under the government's 'Make in India' initiative. Notably, on July 18, BEML had also announced a separate order worth ₹185.65 crore from the Ministry of Defence (E-in-C) for the supply of bulldozers. That earlier order, which was made in the normal course of business, further deepened the company's long-standing relationship with the Ministry and added to its already strong defence-focused order pipeline. While the bulldozer order is unrelated to the latest HMV contract, both reinforce BEML's critical role in supporting India's defence infrastructure through consistent and high-quality equipment deliveries. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
8 hours ago
- Business Upturn
Dr Reddy's Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up
Dr. Reddy's Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported a net profit of ₹1,417.8 crore, up 1.8% from ₹1,392 crore in the same quarter last year. Revenue for the quarter stood at ₹8,545 crore, marking a strong 11.4% year-on-year (YoY) growth compared to ₹7,672.7 crore in Q1 FY25. The company's operating performance also showed improvement, with EBITDA rising 5% YoY to ₹2,278 crore, up from ₹2,160 crore in the previous year. However, the EBITDA margin contracted to 26.7%, compared to 28.2% in Q1 FY25, indicating cost pressures or product mix changes impacting profitability. One key weak spot was in the North American market, where sales declined by 11% YoY to ₹3,410 crore, down from ₹3,846 crore. This drop may reflect pricing pressure and competitive dynamics in the generics space. In the meantime, Dr Reddy's Laboratories shares closed at ₹1,248.00 today, slightly higher than the opening price of ₹1,240.20. The stock touched an intraday high of ₹1,252.10 and a low of ₹1,231.00 during the session. Over the past year, the stock has seen a 52-week high of ₹1,421.49 and a low of ₹1,020.00. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
